Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy

2 februari 2016 bijgewerkt door: University of Manitoba

Effect of a Plant Sterol-Fortified Low-fat Milk Product on Plasma Lipid Levels of Humans in Relation to Different Infant Feeding Practices and Later Life Cholesterol Metabolism

The overall goal of this clinical study is to investigate how dietary cholesterol intake influences the plasma Total cholesterol (TC), LDL-Cholesterol levels and cholesterol metabolism between adults who had been breast-fed as infants as a function of the duration of breast feeding and quantity of early cholesterol intake. The study also aims to evaluate the effect of a plant sterol formulation in low fat milk shake in modulating the lipid profile favorably in the study population.

Studie Overzicht

Toestand

Onbekend

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Hypothesis 1: To determine the responsiveness of plasma lipid profile including Total cholesterol and LDL cholesterol concentrations to high and low cholesterol diets in adults who been breast-fed as infants for different durations

Hypothesis 2: To determine if differences exist in rates of cholesterol absorption and synthesis in adults, and whether such differences respond to variations in cholesterol intake, between individuals who were breast for different durations.

Hypothesis 3: Consumption of a plant sterol formulation in low-fat milk product will favorably alter lipid profiles compared with control in the study population.

This is a free-living, randomized, crossover trial. This trial is modeled after previously successful functional food trial at the investigators clinic, consistent with current recommendations to decrease Cardiovascular diseases (CVD) risk and improve circulating lipid profiles. The proposed study will include three treatment phases of 4 weeks each, separated by 4-week washout intervals:

Phase 1: Study diets with placebo (240 ml of 2% milk shake; 50 mg cholesterol).

Phase 2: Study diets with enriched cholesterol (240ml of 2% milk shake; 600 mg cholesterol).

Phase 3: A study diet with plant sterols (240 ml of 2% milk shake;2.0 g/d of plant sterols/240 ml serving; 50 mg cholesterol).

During each treatment period participants will consume their supper time meal along with assigned test product. Consumption of the suppertime meals and the test products will be monitored by a clinical coordinator to ensure compliance. Participants will be asked to fill out a 3-day food diary at the beginning and end of each experimental period.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

55

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3T 2N2
        • Richardson Centre for Functional Foods and Nutraceuticals

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Triglycerides (TG) <3.0 mmol/L
  • Body mass index (BMI) between 20 and 30 kg/m2
  • Participants must have been breast-fed at least during the first 6 months of their life

Exclusion Criteria:

  • History of recent (i.e. less than 1 month) or chronic use of oral hypolipidemic therapy, including fish oils, or probucol within the last 3 months
  • History of chronic use of alcohol (>2 drinks/d), smoking, systemic antibodies, corticosteroids, androgens, or phenytoin
  • Myocardial infarction, coronary artery bypass, kidney disease, liver disease or other major surgical procedures within the last six months,
  • Sitosterolemic patients
  • Recent onset of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, diabetes, or significant current (i.e. onset within past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year)
  • Exercise greater than walking or running 15 miles/wk or 4,000 kcal/wk
  • Participants who have not been breast-fed at all
  • Pregnant or planning for pregnancy during the next 5 month period

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: High cholesterol
600 mg cholesterol/day in 240 ml milk shake
Ander: High cholesterol
Experimenteel: Plant sterols
2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
Ander: Plant Sterols
Placebo-vergelijker: Placebo
50 mg cholesterol/day in 240 ml of milk shake
Ander: Placebo

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Change in LDL-cholesterol
Tijdsspanne: Day 1,2 & 29,30 of each of the 3 phases. Each phase duration is 1 month
Day 1,2 & 29,30 of each of the 3 phases. Each phase duration is 1 month

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Cholesterol Absorption
Tijdsspanne: Day 26-30 of each of the 3 phases. Each phase duration is 1 month
On day 26 of each dietary phase,a 12-hr fasting blood sample will be obtained to represent stable isotope baseline, after which participants will ingest 75 mg of the stable carbon isotope [3,4-13C] cholesterol stable isotope (13C-cholesterol)dissolved in 5 g of margarine and spread on half of an English muffin. Fasting blood samples will be taken also on days 27, 28, and 29 to monitor isotopic enrichment/decay levels. Free cholesterol extracted from the Red Blood Cell (RBC) fraction of blood will be used to determine 13C-cholesterol enrichment using on-line gas chromatography (GC)/combustion/isotope ratio mass spectrometry (IRMS)using previously established methods. Carbon-di-oxide (CO2) gas will be analyzed for 13C cholesterol enrichment against the Pee Dee Belemnite (PDB). From 24 to 96 hr, cholesterol absorption will be presented as area under the 13C cholesterol RBC enrichment curve calculated by the Number cruncher statistical system (NCSS) statistical software.
Day 26-30 of each of the 3 phases. Each phase duration is 1 month
Change in Cholesterol Synthesis
Tijdsspanne: Day 26-30 of each of the 3 phases. Each phase duration is 1 month
On day 29 prior to breakfast, participants will consume 0.7 g/kg estimated body water (estimated at 60% of total body weight) of deuterium oxide (2H) as a tracer to measure cholesterol synthesis. Fasting blood sample will be collected after 24 hr (96 h after initial isotope administration) in order to monitor the change in deuterium enrichment within red blood cell (RBC) free cholesterol as an index of cholesterol synthesis.Free cholesterol will be extracted from RBC and water from plasma will be isolated using the blood samples collected from day 26-30 each phase. Cholesterol deuterium enrichment will be determined through being expressed relative to a series of standards using a GC/pyrolysis/IRMS using previously established methods. Cholesterol fractional synthesis rate (FSR) (% per day)will be calculated as the rate of incorporation of deuterium within the body water pool into RBC cholesterol pools by measuring the deuterium RBC enrichment over 24 hr.
Day 26-30 of each of the 3 phases. Each phase duration is 1 month

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Manitoba

Onderzoekers

  • Hoofdonderzoeker: Peter JH Jones, PhD, University of Manitoba

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 maart 2013

Primaire voltooiing (Werkelijk)

1 september 2013

Studie voltooiing (Verwacht)

1 juni 2016

Studieregistratiedata

Eerst ingediend

21 maart 2013

Eerst ingediend dat voldeed aan de QC-criteria

1 april 2013

Eerst geplaatst (Schatting)

8 april 2013

Updates van studierecords

Laatste update geplaatst (Schatting)

3 februari 2016

Laatste update ingediend die voldeed aan QC-criteria

2 februari 2016

Laatst geverifieerd

1 maart 2013

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • B2013:019

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren